Unknown

Dataset Information

0

Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5.


ABSTRACT: Programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) blocking therapy has become a major pillar of cancer immunotherapy. Compared with antibodies targeting, small-molecule checkpoint inhibitors which have favorable pharmacokinetics are urgently needed. Here we identified berberine (BBR), a proven anti-inflammation drug, as a negative regulator of PD-L1 from a set of traditional Chinese medicine (TCM) chemical monomers. BBR enhanced the sensitivity of tumour cells to co-cultured T-cells by decreasing the level of PD-L1 in cancer cells. In addition, BBR exerted its antitumor effect in Lewis tumor xenograft mice through enhancing tumor-infiltrating T-cell immunity and attenuating the activation of immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T-cells (Tregs). BBR triggered PD-L1 degradation through ubiquitin (Ub)/proteasome-dependent pathway. Remarkably, BBR selectively bound to the glutamic acid 76 of constitutive photomorphogenic-9 signalosome 5 (CSN5) and inhibited PD-1/PD-L1 axis through its deubiquitination activity, resulting in ubiquitination and degradation of PD-L1. Our data reveals a previously unrecognized antitumor mechanism of BBR, suggesting BBR is small-molecule immune checkpoint inhibitor for cancer treatment.

SUBMITTER: Liu Y 

PROVIDER: S-EPMC7745128 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity <i>via</i> inhibiting the deubiquitination activity of CSN5.

Liu Yang Y   Liu Xiaojia X   Zhang Na N   Yin Mingxiao M   Dong Jingwen J   Zeng Qingxuan Q   Mao Genxiang G   Song Danqing D   Liu Lu L   Deng Hongbin H  

Acta pharmaceutica Sinica. B 20200630 12


Programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) blocking therapy has become a major pillar of cancer immunotherapy. Compared with antibodies targeting, small-molecule checkpoint inhibitors which have favorable pharmacokinetics are urgently needed. Here we identified berberine (BBR), a proven anti-inflammation drug, as a negative regulator of PD-L1 from a set of traditional Chinese medicine (TCM) chemical monomers. BBR enhanced the sensitivity of tumour cells to co-cultured  ...[more]

Similar Datasets

| S-EPMC5171205 | biostudies-literature
| S-EPMC4873287 | biostudies-literature
| S-EPMC10042735 | biostudies-literature
| S-EPMC8329431 | biostudies-literature
| S-EPMC11208742 | biostudies-literature
| S-EPMC11831439 | biostudies-literature
| S-EPMC8322265 | biostudies-literature
| S-EPMC7244707 | biostudies-literature
| S-EPMC5051664 | biostudies-literature